Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.62 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.48 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.48 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.48 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.48 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.48 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.48 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.48 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.48 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.48 |
| ▸ | LONP1 | P36776 | 2/20 | 0.48 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.48 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.48 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353153 | 0.83 | S1PR1 (0.72) | S1PR1RAB9ANPC1SMN1; SMN2TAOK1 | |
| SCHEMBL12044866 | 0.82 | S1PR1 (0.62) | S1PR1TAOK1TAOK3 | |
| SCHEMBL1373002 | 0.81 | S1PR1 (0.71) | S1PR1TAOK1TAOK3 | |
| SCHEMBL1373005 | 0.81 | S1PR1 (0.71) | S1PR1TAOK1TAOK3 | |
| SCHEMBL1374544 | 0.81 | UGCG (0.64) | S1PR1 | |
| SCHEMBL9985096 | 0.81 | S1PR1 (0.61) | S1PR1RAB9ASMN1; SMN2TAOK1TAOK3 | |
| SCHEMBL1375135 | 0.81 | S1PR1 (0.64) | S1PR1TAOK1TAOK3 | |
| SCHEMBL12044416 | 0.81 | S1PR1 (0.56) | S1PR1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1372313 | 0.81 | S1PR1 (0.66) | S1PR1RAB9ANPC1SMN1; SMN2TAOK1 | |
| SCHEMBL12044690 | 0.80 | S1PR1 (0.60) | S1PR1POLBTAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2349252-A2 | SYNERGISTIC COMBINATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045601-A2 | SYNERGISTIC EFFECTS BETWEEN SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885CTSS 2920/4885PSMB11 2237/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885CTSS 3141/4885PSMB11 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.